The companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Fluocinolone Acetonide Oil (RLD Derma-Smoothe/FS®) had estimated annual sales of USD 10 million in the U.S. (IQVIA MAT June 2023)
Subscribe To Our Newsletter & Stay Updated
